focus -WSS

focus

author：entertainment 2025-09-27 17:03:15 - browse：7439

Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： BIO selects John Crowley as new CEO

Wikipedia

focus

WSS

Organ aging and disease risk measured by new blood test

Mayo Clinic plans $5B tech

Roche's accidental data boosts hopes for anti

FDA investigates CAR

Former Pear Therapeutics executives start new VC firm

How to pay for weight loss drugs and save Medicare

explore

focus

Wikipedia

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Diagnostic tests are hitting their mathematical limits

New air purifier tech could be key to improving indoor air quality

Listen: Vivek Ramaswamy's star turn & leaky drug data

Dobbs anniversary: the lost opportunity of abortion as health care

J&J to emphasize cancer drugs, stop much of its vaccine research

Hollywood unions extend contract negotiations for actors

Will the market for weight loss drugs really reach $100 billion?

Hepatitis C has a cure — but many Americans still lack access to it

Rep. Raul Ruiz on the physician shortage and more

focus

Flagship Pioneering launches a new biotech in two countries

Fetal surgery at risk from Dobbs and new abortion restrictions

What to do when lifesaving products contribute to climate change

How to pay for weight loss drugs and save Medicare

Health officials lay out plans to cope with respiratory virus season

Roche's accidental data boosts hopes for anti

Wikipedia

leisure time

focus

entertainment